this issue. How expertise of surgeon be evaluated (particularly in MIS) as this may be the major strength/weakness point of this study. The details described under the heading 'study centers and surgeon selection' seems to be inadequate. -For more clarification, it would be better to state the operation definitions of all clinical terms (i.e. definition of each survival outcome) in a separate heading. -In Page 8, the authors stated that they will assess OS and PFS as a secondary objective. Is it suitable to determine PFS in this group of patients? -One of the important results that should be assesses is the difference of the type of cancer recurrence among patients undergoing MIS and laparotomy approach. In LACC study, the pattern of cancer recurrence is quite different between these two surgical approach. -I would recommend the authors to compare the results (at least for primary objective) by repeating analyses as per either intention to treat or per protocol basis. -The authors stated that para-aortic lymphadenectomy will be done on some selected participants. It would be better to clearly stated the criteria to do this procedure.
-Do the authors set the central pathology review? Please state in the protocol -The staging procedures for cervical cancer should be standardized across the study participating centers and have to be detailed in the study protocol.
REVIEWER
David Moriña Soler Universitat Autònoma de Barcelona, Spain REVIEW RETURNED 11-Mar-2019
GENERAL COMMENTS
This is a well written manuscript, addressing an interesting issue with practical consequences in the clinical treatment of cervical cancer. However, there are several issues regarding the planned statistical analyses that should be addressed: 1. Regarding the sample size calculation, a p-value adjustment method is mentioned (Pocock). A reference is necessary, as I'm afraid most readers of the journal won't be aware of this methodology. 2. The statistical analyses described in page 16 should be better explained. In particular, how will the distinction between normally distributed continuous variables and non-normally distributed variables be conducted? If I have understood correctly, as a consequence of the study design, the outcomes will be measured at several time points, and therefore more suitable alternative to ttests should be used to compare continuous variables (and similarly for categorical variables).
3. Regarding survival analysis, the proportional hazards assumption should be tested. How will this be done should be specified in the protocol manuscript. Alternative approaches in case PH hypothesis does not hold should be presented.
VERSION 1 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
Reviewer: 1
Reviewer Name: Jose Alejandro Rauh-Hain
Institution and Country: UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
The authors present the protocol of a phase 3 multi-center randomized controlled trial to evaluate minimally-invasive surgery in women with early stage cervical cancer. The authors state that they already starting recruiting patients in their study and therefore I don't think I can provide any meaningful suggestions to their protocol or analysis plan, although their protocol is comprehensive and addresses an important question. I believe the statistical analysis requires specialist statistical review from the Journal. There are grammatical errors through the manuscript.
Response: great thanks for your invaluable instructions! Great thanks for your opinions, we have reviewed the statistical analysis and modified the grammatical errors.
Reviewer: 2
Reviewer Name: Chumnan Kietpeerakool Institution and Country: Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University, Thailand
This study is investigating the effectiveness of different surgical techniques of radical hysterectomy for early stage cervical cancer. As partly mentioned by the authors, the results of LACC trial against the use of MIS for radical hysterectomy in terms of lower survival and high rate of cancer recurrence. These findings have raised the concern about the appropriateness when conducting the additional RCT comparing MIS to laparotomy radical hysterectomy unless the differences between LACC and this protocol have been clearly emphasized by the authors.
Response: great thanks for your invaluable instructions and appreciations! We have intently followed your instructions to revise the text.
The authors stated that this study will evaluate the impact of the different surgeon on the outcomes. However, there are no data on how to do so. How the surgeon be classified during determining this issue. How expertise of surgeon be evaluated (particularly in MIS) as this may be the major strength/weakness point of this study. The details described under the heading 'study centers and surgeon selection' seems to be inadequate.
Response: great thanks for your invaluable instructions! To address your question, we stated in the section of "Intervention -Study centers and surgeon selection", that "To qualify the skills and learning curves of these surgeons, at least 100 unselected, consecutive RH cases for early-stage cervical cancer in their past decade of practice will be retrospectively collected for the analysis of surgical and survival outcomes" (page 12, line 218-221). Beside, according to your instructions, we supplemented other explanation: "These data will be used to verify the learning curves of MIS and ARH in these surgeons in a retrospective cohort study (registration No. NCT03738969, SACCC, clinicaltrials.gov)." (page 12-13, line 221-223) -For more clarification, it would be better to state the operation definitions of all clinical terms (i.e. definition of each survival outcome) in a separate heading.
Response: great thanks for your invaluable instructions! We have supplemented the definition under the headline of "Surgical treatment" (page 13-14, line 235-254). A total 6 items were defined in the modified text.
-
In Page 8, the authors stated that they will assess OS and PFS as a secondary objective. Is it suitable to determine PFS in this group of patients?
Response: great thanks for your invaluable instructions! We have deleted the PFS as a secondary objective as this item is not suitable to compare the prognosis of early stage cervical cancer. Thanks for your reminding! -One of the important results that should be assesses is the difference of the type of cancer recurrence among patients undergoing MIS and laparotomy approach. In LACC study, the pattern of cancer recurrence is quite different between these two surgical approach.
Response: great thanks for your invaluable instructions! We have stressed your issues in page 9, line 152 under the headline of "Secondary objectives" according to your instructions.
-I would recommend the authors to compare the results (at least for primary objective) by repeating analyses as per either intention to treat or per protocol basis.
Response: great thanks for your invaluable instructions! We have stressed your issues in page 18, line 340-341 under the headline of "Statistical analysis" according to your instructions. The survival outcomes will be compared according to intention to treat and per protocol basis.
The authors stated that para-aortic lymphadenectomy will be done on some selected participants. It would be better to clearly stated the criteria to do this procedure.
Response: great thanks for your invaluable instructions! We have stressed your issues in page 13, line 230-233 under the headline of "Surgical treatment" according to your instructions: Pelvic lymphadenectomy will be performed in all patients, and para-aortic lymphadenectomy will be performed in selected patients of stage IB1 who are suspected to have metastasis to para-aortic lymph nodes during the intraoperative inspection according to the NCCN guideline.
Do the authors set the central pathology review? Please state in the protocol Response: great thanks for your invaluable instructions! We have stressed your issues in page 15, line 283-284 under the headline of "Measurement" according to your instructions. An independent pathological center will be set to review all the samples from all the study centers.
The staging procedures for cervical cancer should be standardized across the study participating centers and have to be detailed in the study protocol.
Response: great thanks for your invaluable instructions! We have stressed your issues in page 15-16, line 283-289 under the headline of "Measurement" according to your instructions: A standardized FIGO staging system of 200933 should be executed in all study centers, since this version of staging bases on the preoperative evaluations. In this system, IA1 has measured stromal invasion of ≤3.0 mm in depth and extension of ≤7.0 mm, IA2 has measured stromal invasion of >3.0 mm and not >5.0 mm with an extension of not >7.0 mm, and IB1 had clinically visible lesions ≤4.0 cm in greatest dimension limited to the cervix uteri or pre-clinical cancers greater than stage IA.
Reviewer: 3
Reviewer Name: David Moriña Soler Institution and Country: Universitat Autònoma de Barcelona, Spain
